Galderma Highlights Fast Onset, Durability Data For Potential Botox Rival

 
• By Jessica Merrill

The company reported positive data from two Phase IIIb trials testing RelabotulinumtoxinA and said it hopes to refile a BLA for the aesthetic dermatology product soon.

Wrinkles
Galderma is looking to compete in the market dominated by Botox • Source: Shutterstock

More from Clinical Trials

More from R&D